Stockreport

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]

Revolution Medicines, Inc.  (RVMD) 
PDF G&A Expenses: $24.0 million for Q3 2024, up from $15.5 million in Q3 2023. Net Loss: $156.3 million for Q3 2024, compared to $108.4 million in Q3 2023. Projected Fu [Read more]